Skip to main content

We've updated our Privacy Policy. Questions? Email us any time at privacy@ground.news

SubscribeLogin
Published • loading... • Updated

Aprea Expands APR-1051 Trial as Enrollment Accelerates

Summary by MyChesCo
DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) is expanding enrollment and broadening the clinical development strategy for its investigational WEE1 inhibitor APR-1051 as the company advances a Phase 1 …
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

MyChesCoMyChesCo

Aprea Expands APR-1051 Trial as Enrollment Accelerates

DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) is expanding enrollment and broadening the clinical development strategy for its investigational WEE1 inhibitor APR-1051 as the company advances a Phase 1 …

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MyChesCo broke the news on Wednesday, August 5, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Doylestown icon

Doylestown

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal